What indicators need to be tested regularly during larotrectinib treatment?

Larotinib is a targeted drug targeting NTRK gene fusion and is widely used in the treatment of a variety of solid tumors carrying NTRK fusion mutations. During treatment, regular monitoring of relevant indicators is crucial to evaluate drug efficacy and safety. First, imaging examinations are a key means of assessing tumor response. Through imaging examinations such as CT, MRI or PET-CT, we can intuitively understand the changes in tumor size and metastasis, and thus determine whether the treatment effect is ideal.

Secondly, laboratory testing is also essential. Patients should undergo regular blood routine examinations during treatment to monitor white blood cell, platelet and red blood cell counts to prevent possible bone marrow suppression. In addition, liver and kidney function tests are equally important, because the metabolism of larotrectinib mainly depends on the liver, and abnormal liver function may affect drug metabolism, leading to increased toxicity. By detecting indicators such as ALT, AST, total bilirubin, serum creatinine, and urea nitrogen, potential liver and kidney damage can be detected and treated in a timely manner.

Thirdly, cardiac function monitoring also needs attention. Some patients may develop QT interval prolongation or other arrhythmias while using targeted drugs. It is recommended to perform electrocardiogram (ECG) regularly during treatment, especially for patients with heart disease or concurrent use of other drugs that may affect heart function, to reduce cardiovascular risk.

Finally, patients should also pay attention to clinical symptoms and changes in quality of life. If they experience severe discomfort, persistent fatigue, dyspnea or neurological symptoms, they should promptly inform their doctor. Comprehensive monitoring of multiple indicators can help doctors adjust treatment plans, ensure the safety and effectiveness of treatment to the greatest extent, and improve patients' long-term survival rate and quality of life.

Reference materials:https://www.vitrakvi.com/